MX2010003599A - Intermediarios y metodos para la sintesis de analogos de halicondrina b. - Google Patents

Intermediarios y metodos para la sintesis de analogos de halicondrina b.

Info

Publication number
MX2010003599A
MX2010003599A MX2010003599A MX2010003599A MX2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A MX 2010003599 A MX2010003599 A MX 2010003599A
Authority
MX
Mexico
Prior art keywords
halichondrin
analogs
synthesis
methods
intermediates
Prior art date
Application number
MX2010003599A
Other languages
English (en)
Spanish (es)
Inventor
Atsushi Endo
Jing Li
Charles Chase
Francis G Fang
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2010003599A publication Critical patent/MX2010003599A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
MX2010003599A 2007-10-03 2008-10-03 Intermediarios y metodos para la sintesis de analogos de halicondrina b. MX2010003599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99762507P 2007-10-03 2007-10-03
PCT/US2008/078762 WO2009046308A1 (en) 2007-10-03 2008-10-03 Intermediates and methods for the synthesis of halichondrin b analogs

Publications (1)

Publication Number Publication Date
MX2010003599A true MX2010003599A (es) 2010-09-10

Family

ID=40019255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003599A MX2010003599A (es) 2007-10-03 2008-10-03 Intermediarios y metodos para la sintesis de analogos de halicondrina b.

Country Status (11)

Country Link
US (6) US8093410B2 (enExample)
EP (2) EP2578576B9 (enExample)
JP (1) JP5735277B2 (enExample)
CN (3) CN104311571B (enExample)
BR (1) BRPI0817909B1 (enExample)
CA (1) CA2701534C (enExample)
IL (1) IL204791A (enExample)
MX (1) MX2010003599A (enExample)
RU (1) RU2489437C2 (enExample)
SG (1) SG10201811715YA (enExample)
WO (1) WO2009046308A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2682878B2 (ja) 1989-11-27 1997-11-26 上村工業株式会社 シールド付き電気めっき装置
CN1216051C (zh) 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
USRE45324E1 (en) 2004-06-03 2015-01-06 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
MX2010003599A (es) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediarios y metodos para la sintesis de analogos de halicondrina b.
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
DE102009012660A1 (de) * 2009-03-13 2010-09-16 H.C. Starck Clevios Gmbh Polymerbeschichtungen mit verbesserter Temperaturstabilität
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
MX2012008510A (es) 2010-01-26 2012-11-21 Eisai R&D Man Co Ltd Derivados de furo [3, 2-b] pirano utiles en la sintesis de analogos de halicondrina b.
CN102225921B (zh) * 2011-04-26 2013-04-24 中国人民解放军第二军医大学 一种环戊烷聚酮类化合物simplextone A及其用途
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
AU2013353745A1 (en) 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
RU2672585C2 (ru) 2013-06-26 2018-11-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
CN109942560B (zh) 2013-11-04 2022-06-17 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
EP3505520A1 (en) 2013-12-06 2019-07-03 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
US20170100367A1 (en) 2014-05-28 2017-04-13 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
WO2016003975A1 (en) 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
WO2016038624A1 (en) * 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
RU2737216C2 (ru) 2015-03-04 2020-11-26 Мерк Шарп Энд Дохме Корп. Комбинация антагониста pd-1 и эрибулина для лечения рака
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX392296B (es) 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
SG11201806133UA (en) 2016-02-12 2018-08-30 Eisai R&D Man Co Ltd Intermediates in the synthesis of eribulin and related methods of synthesis
CN114191563A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
EP3478691A4 (en) * 2016-06-30 2020-07-22 Eisai R&D Management Co., Ltd. REACTION OF PRINS AND USEFUL INTERMEDIARIES IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ITS ANALOGUES
EP3525818A1 (en) 2016-10-14 2019-08-21 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
ES2931533T3 (es) 2017-04-05 2022-12-30 Harvard College Compuesto macrocíclico y usos del mismo
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
CN111433211B (zh) * 2017-07-06 2024-05-07 哈佛大学的校长及成员们 软海绵素的合成
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
EP4403560A3 (en) 2017-11-15 2024-10-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN111868044B (zh) 2018-01-03 2024-07-19 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US12247239B2 (en) 2019-06-21 2025-03-11 Council Of Scientific & Industrial Research Chemo-enzymatic process for the preparation of homopropargylic alcohol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2027890C3 (de) * 1970-06-06 1979-02-01 Kali Chemie Ag 8-AIkoxy oder -Benzyloxy-3-methyl-lO- methylen-2,9-dioxatricyclo-(43,l,03,7 )-decan-4-one und 8-AIkoxy oder 8-Benzyloxy-3,10-dimethyl-2,9dioxatricyclo- (43,1,O" )-decan-4-one
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US4086245A (en) * 1976-12-09 1978-04-25 The Upjohn Company Antibiotics 7-O-alkylnogarols
SU722912A1 (ru) * 1978-03-06 1980-03-25 Уфимский Нефтяной Институт Способ получени 5-метил/-4оксо3,6,8-триоксабицикло/ (3,2,1)-октана
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (enExample) 1992-09-09 1995-09-01 Hoechst Ag
WO1998009942A1 (en) 1996-09-06 1998-03-12 Eli Lilly And Company Catalytic selective sulfonylation process
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
CN1216051C (zh) * 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
DE10106647A1 (de) 2001-02-12 2002-08-22 Univ Hannover Ratjadon-Derivate zum Hemmen des Zellwachstums
CN109180615A (zh) * 2004-06-03 2019-01-11 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
USRE45324E1 (en) 2004-06-03 2015-01-06 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
US7915457B2 (en) 2005-09-26 2011-03-29 Symrise Gmbh & Co. Kg Intramolecular Prins reaction and catalysts suitable therefor
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
MX2010003599A (es) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediarios y metodos para la sintesis de analogos de halicondrina b.
WO2009064029A1 (en) * 2007-11-16 2009-05-22 Eisai R & D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
US8598373B2 (en) * 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
MX2012008510A (es) 2010-01-26 2012-11-21 Eisai R&D Man Co Ltd Derivados de furo [3, 2-b] pirano utiles en la sintesis de analogos de halicondrina b.
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN109942560B (zh) 2013-11-04 2022-06-17 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
EP3505520A1 (en) 2013-12-06 2019-07-03 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
MX392296B (es) 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
SG11201806133UA (en) 2016-02-12 2018-08-30 Eisai R&D Man Co Ltd Intermediates in the synthesis of eribulin and related methods of synthesis
EP3478691A4 (en) 2016-06-30 2020-07-22 Eisai R&D Management Co., Ltd. REACTION OF PRINS AND USEFUL INTERMEDIARIES IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ITS ANALOGUES
WO2018217894A1 (en) 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
CN111868044B (zh) 2018-01-03 2024-07-19 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物

Also Published As

Publication number Publication date
CN101883763A (zh) 2010-11-10
US8987479B2 (en) 2015-03-24
EP2578576B9 (en) 2016-09-14
CN104311571B (zh) 2019-07-02
EP2200992A1 (en) 2010-06-30
CA2701534C (en) 2017-02-21
US20160214992A1 (en) 2016-07-28
SG10201811715YA (en) 2019-02-27
BRPI0817909A2 (pt) 2015-04-07
CN108948039B (zh) 2021-12-31
JP2010540658A (ja) 2010-12-24
US20190263826A1 (en) 2019-08-29
RU2010117520A (ru) 2011-11-10
US20090198074A1 (en) 2009-08-06
CN108948039A (zh) 2018-12-07
US10214539B2 (en) 2019-02-26
CN101883763B (zh) 2016-04-20
EP2578576A1 (en) 2013-04-10
WO2009046308A1 (en) 2009-04-09
JP5735277B2 (ja) 2015-06-17
IL204791A (en) 2017-06-29
EP2578576B1 (en) 2016-03-23
CA2701534A1 (en) 2009-04-09
RU2489437C2 (ru) 2013-08-10
IL204791A0 (en) 2010-11-30
US9802953B2 (en) 2017-10-31
CN104311571A (zh) 2015-01-28
US20150225415A1 (en) 2015-08-13
EP2200992B1 (en) 2014-02-26
BRPI0817909B1 (pt) 2022-06-21
US9604993B2 (en) 2017-03-28
US8093410B2 (en) 2012-01-10
US20120095242A1 (en) 2012-04-19
US10717743B2 (en) 2020-07-21
US20180037588A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
MX2010003599A (es) Intermediarios y metodos para la sintesis de analogos de halicondrina b.
IL201852A0 (en) Process for the synthesis of ramelteon and its intermediates
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
MX2009009773A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
MY155424A (en) Processes for the preparation of aminosulfone compounds
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
MY163339A (en) A method of producing ingenol-3-angelate
GB0702854D0 (en) Method for the synthesis of sucrose-6-esters
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
WO2010068282A3 (en) Compositions and methods for synthesis of hydrogen fuel
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2009013921A (es) Material refractario sin forma, un proceso para producir un material refractario sin forma, humedo como la tierra, y al uso del material refractario sin forma.
MX2009010903A (es) Metodos para preparar compuestos basados en imidazol.
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
AP2291A (en) Production of synthesis gas.
TWI374886B (en) Processes for preparing intermediates of pemetrexed
MX2008011666A (es) Sintesis de compuestos que modulan la actividad de la trombopoyetina.
ZA201000394B (en) Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
TW200800986A (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
TW200728310A (en) Process for the preparation of ferri-succinylcasein
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.
AU2009235634A8 (en) Substituted sulfonamide derivatives
MX2010003056A (es) Polimorfos de valomaciclovir.